Company research
AETHLON MEDICAL INC
CIK 882291Updated Sep 27, 2026
SecurityAEMD · NASDAQ · equity
Name history
BISHOP EQUITIES INC · through Mar 13, 2000
AEMD price & chart
Loading TradingView…
NASDAQ:AEMD on TradingView ↗About the company
We are a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier has demonstrated the potential to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and metastasis, and in life-threatening infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a “Breakthrough Device” for two independent indications:
In the news
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities ↗
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million News provided by Aethlon Medical, Inc. Dec 05, 2025, 09:15 ET Share this article Share to X Share this article Share to X SAN DIEGO , Dec. 5, 2025 /PRNew ↗
Recent filings
425 filing
Entry into a Material Definitive Agreement · Changes in Control of Registrant · Regulation FD Disclosure
Items 1.01, 5.01, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
DEFA14A filing
DEF 14A filing
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 6,333,107Source | 7,359,534Source | 8,245,982Source | 17,508,940Source |
| Property, Plant and Equipment, NetUSD | 356,822Source | 676,220Source | 1,015,229Source | 1,144,004Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,026,458Source | 5,501,261Source | 5,441,978Source | 14,532,943Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 0Source |
| Assets, CurrentUSD | 5,569,537Source | 5,949,800Source | 6,225,788Source | 15,090,566Source |
| Prepaid Expense and Other Assets, CurrentUSD | 332,094Source | 448,539Source | 505,983Source | 557,623Source |
| Operating Lease, Right-of-Use AssetUSD | 307,820Source | 601,846Source | 883,054Source | 1,151,909Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,446,835Source | 2,236,004Source | 2,479,650Source | 2,444,731Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,570Source | 2,586Source | 2,629Source | 22,994Source |
| Additional Paid in CapitalUSD | 180,023,691Source | 173,092,894Source | 160,337,371Source | 157,405,911Source |
| Retained Earnings (Accumulated Deficit)USD | -175,106,286Source | -167,954,817Source | -154,566,728Source | -142,358,555Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -32,703Source | -17,133Source | -6,940Source | -6,141Source |
| Stockholders' Equity Attributable to ParentUSD | 4,886,272Source | 5,123,530Source | 5,766,332Source | 15,064,209Source |
| Liabilities and EquityUSD | 6,333,107Source | 7,359,534Source | 8,245,982Source | 17,508,940Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,446,835Source | 1,899,286Source | 1,829,899Source | 1,505,089Source |
| Operating Lease, Liability, CurrentUSD | 336,718Source | 313,033Source | 290,565Source | 269,386Source |
| Accounts Payable, CurrentUSD | 384,550Source | 534,524Source | 777,862Source | 432,890Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 336,718Source | 649,751Source | 939,642Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 250,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -12,029,786Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 323,653Source | 339,559Source | 359,057Source | 240,892Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 278,547Source | 415,234Source | 1,219,370Source | 1,051,898Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | 0Source | -127,965Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -6,998,392Source | -7,645,532Source | -10,129,810Source | -10,505,128Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -3,704Source | 0Source | -250,867Source | -943,109Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 3,704Source | 0Source | 250,867Source | 943,109Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 10,915Source | 18,927Source | 34,778Source | 12,493Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,521,904Source | 7,727,384Source | 1,287,605Source | 8,914,718Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -473,688Source | 69,590Source | -9,090,965Source | -2,533,519Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,125,386Source | 5,599,074Source | 5,529,484Source | 14,620,449Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,504Source | -12,262Source | 2,107Source | -5,957Source |
| Additional Financial Items | ||||
| Amortization of Deferred ChargesUSD | — | — | — | 0Source |
| Amortization of Intangible AssetsUSD | 550Source | 550Source | 550Source | 550Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 250,000Source |
| DepreciationUSD | 323,102Source | 339,009Source | 358,507Source | 240,342Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 0Source | -21,135Source | — |
| General and Administrative ExpenseUSD | 2,696,445Source | 3,243,181Source | 3,903,191Source | 4,481,303Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 14,372Source | — | — | — |
| Investment Income, InterestUSD | 156,534Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -7,151,469Source | -13,388,089Source | -12,208,174Source | -12,029,786Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Nonoperating Income (Expense)USD | 142,162Source | — | — | — |
| Operating ExpensesUSD | 7,293,631Source | 9,341,365Source | 12,636,568Source | 12,472,883Source |
| Operating Lease, ExpenseUSD | 464,350Source | 421,789Source | 420,353Source | 519,000Source |
| Proceeds from Issuance of Common StockUSD | 6,901,465Source | 3,539,907Source | 1,322,383Source | — |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 574,245Source |
| Operating Income (Loss)USD | -7,293,631Source | -9,341,365Source | -12,636,568Source | -11,898,638Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -7,151,469Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -7,151,469Source | -13,388,089Source | -12,208,174Source | -12,029,786Source |
| Earnings Per Share, BasicUSD per share | -10.61Source | -8.58Source | -4.86Source | -0.59Source |
| Earnings Per Share, DilutedUSD per share | -10.61Source | -8.58Source | -4.86Source | -0.59Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 673,945Source | 1,560,839Source | 2,512,774Source | 20,537,434Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 673,945Source | 1,560,839Source | 2,512,774Source | 20,537,434Source |
| Interest Expense (non-operating)USD | 14,372Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 550Source | 550Source | 550Source | 550Source |
| General and Administrative ExpenseUSD | 2,696,445Source | 3,243,181Source | 3,903,191Source | 4,481,303Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -6,347,160Source | — | — | — |
| Interest ExpenseUSD | — | 10,109Source | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | 298,122Source | — | — |
| Interest Income, OtherUSD | — | — | 428,394Source | 10,973Source |
| Investment Income, InterestUSD | 156,534Source | — | — | — |
| Labor and Related ExpenseUSD | 2,788,005Source | 3,874,092Source | 5,206,451Source | 4,443,552Source |
| Nonoperating Income (Expense)USD | 142,162Source | — | — | — |
| Operating ExpensesUSD | 7,293,631Source | 9,341,365Source | 12,636,568Source | 12,472,883Source |
| Operating Lease, ExpenseUSD | 464,350Source | 421,789Source | 420,353Source | 519,000Source |
| Research and Development ExpenseUSD | 1,912,000Source | 2,212,000Source | 2,520,000Source | 2,745,000Source |
Offerings
Registration 333-296933
Registration 333-292598
Registration 333-289745
- Gross proceeds
- 4500000.0
- Net proceeds
- 4218750.0
- Deal price
- 0.9
- Shares
- 5000000
- Offering price
- $0.900
- Ticker
- AEMD
Filing attachments
aethlon_ex107.htm · S-1 · 2026-06-22
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Aethlon Medical Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗aethlon_ex107.htm · S-1 · 2026-01-07
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 AETHLON MEDICAL, INC. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗aethlon_ex107.htm · S-1 · 2025-08-20
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 Aethlon Medical, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗